On April 8, 2021, BioTwin, a Quebec-based biotechnology company, announced the completion of their pre-seed funding round.
The company raised a total of C$2.5 million with the support of private investors and various levels of government. Leading this financing round, BioTwin received support from CTS, a business accelerator in the field of medical technologies.
This financing will accelerate BioTwin’s development of an AI platform used to detect, predict and prevent patients' health various conditions.
A Fasken team composed of Henrick Simard and Vincent Laforest-Lapointe advised BioTwin in connection with this transaction.